40
Participants
Start Date
February 29, 1996
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Antineoplaston therapy (Atengenal + Astugenal)
"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
Burzynski Clinic, Houston
Lead Sponsor
Burzynski Research Institute
OTHER